报价延迟最少15分钟:2025/10/23 21:30 EDT
常规时段
|
|
|
|
|
||||||||||||
|
|
|
|
|
0.7209 
|
|
|
| 价值评估 |
|
盈利(现时/预测)
-1.20/-0.45
|
|
企业价值
14.37M
|
| 资产负债 |
|
每股账面净值
1.72
|
| 现金流量 |
|
现金流量率
--
|
| 损益表 |
|
收益
0
|
|
每股收益
--
|
|
同行比较
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
报价延迟最少15分钟：2025/10/23 21:30 EDT
同行比较之报价最少15分钟延迟
|
业务概览
|
|||
| enVVeno Medical Corp is a late clinical-stage medical device company focused on advancing bioprosthetic (tissue-based) solutions to improve the standard of care for treating venous disease. The company's product, VenoValve, is a surgical replacement venous valve that is currently being evaluated in a U.S. pivotal study. The company is also developing a second product called enVVe, which is a non-surgical, transcatheter-based replacement venous valve. Both the products are designed to act as one-way valves to help assist in propelling blood up the veins of the leg, and back to the heart and lungs. The company has determined that it currently operates in a single segment, Medical Device development, located in asingle geographic location, the United States. |
